NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Lenalidomide for multiple myeloma in people who have received at least one prior therapy

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed: Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:					
	Proposal:	Proposal made by:		Action taken: Removed/Added/Not included/Noted	Justification:

National Institute for Health and Clinical Excellence

1

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of lenalidomide for multiple myeloma in people who have received at least one prior therapy

1	The United Kingdom Myeloma Forum is a charitable organisation made up of health care professionals involved in myeloma research and care. It should therefore be included in Professional groups list not the Patient /Carer group.	Combined response from: British Society of Haematologists Royal College of Pathologists Royal College of Physicians UK Myeloma Forum	Added	UK Myeloma Forum have been moved from the patient/carer group to the professional group on the matrix of consultees and commentators.
2	UK Myeloma forum (they are not a patient/carer group)	Celgene Limited	Added	UK Myeloma Forum have been moved from the patient/carer group to the professional group on the matrix of consultees and commentators.
3.	To the list of professional body consultees the Company suggests British Oncology Pharmacists Association (BOPA)	Celgene Limited	Noted	This organisation is already represented on the matrix of consultees and commentators as Cancer Network Pharmacists Forum following a name change.

2

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of lenalidomide for multiple myeloma in people who have received at least one prior therapy

4.	To the comparator manufacturers we suggest adding Cephalon (liposomal doxorubicin)	Celgene Limited	Added	Celgene added to comparator manufacturers, along with all other manufacturers of doxorubicin.
5.	Given our contentionthat thalidomide is not a valid comparator we suggest removal of Pharmion	Celgene Limited	Noted	Pharmion still kept on matrix as comparator manufacturer.
6.	We request that the Leukaemia Research Fund, MRC Clinical Trials Unit and National Cancer Research Institute should be invited as consultees rather than commentators.	Celgene Limited	Noted & Leukaemia Research Fund added to 'patient' section of consultees.	As per the technology appraisal process, all research organisations are included in the matrix under 'commentators'.
7.	We are called Rarer Cancers Forum not Cancer Macmillan Cancer Relief is re-branded to Macmillan Cancer Support	Rarer Cancers Forum	Noted	Alterations made as requested.

3

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of lenalidomide for multiple myeloma in people who have received at least one prior therapy

8.	Afiya Trust	NICE Secretariat	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Afiya Trust has been added to the matrix under 'patient/carer' groups.
9.	British Ethnic Health Awareness Foundation (BEHAF)	NICE Secretariat	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the British Ethnic Health Awareness Foundation (BEHAF) has been added to the matrix under 'patient/carer' groups.
10.	Policy Research Institute on Ageing and Ethnicity	NICE Secretariat	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Policy Research Institute on Ageing and Ethnicity has been added to the matrix under 'research' groups.

/

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of lenalidomide for multiple myeloma in people who have received at least one prior therapy

11.	Research Institute for the Care of the Elderly	NICE Secretariat	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Research Institute for the Care of the Elderly has been added to the matrix under 'patient/carer' groups.
12.	NHS Alliance	NICE Secretariat	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the NHS Alliance has been added to the matrix under the 'General' group.
13.	National Association of Primary Care	NICE Secretariat	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the National Primary Care has been added to the matrix under the 'General' group.

5

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of lenalidomide for multiple myeloma in people who have received at least one prior therapy

14.	Chinese National Healthy Living Centre	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Chinese National Healthy Living Centre should be added to the matrix under 'patient/carer' groups.
15.	Confederation of Indian Organisations	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Chinese National Healthy Living Centre should be added to the matrix under 'patient/carer' groups.
16.	Equalities National Council	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Chinese National Healthy Living Centre should be added to the matrix under 'patient/carer' groups.

6

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of lenalidomide for multiple myeloma in people who have received at least one prior therapy

17.	Muslim Council of Great Britain	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Muslim Council of Great Britain should be added to the matrix under 'patient/carer' groups.
18.	Muslim Health Network	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Muslin Health Network should be added to the matrix under 'patient/carer' groups.
19.	South Asian Health Foundation	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the South Asian Health Foundation should be added to the matrix under 'patient/carer' groups.

7

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of lenalidomide for multiple myeloma in people who have received at least one prior therapy

20.	African and Caribbean Leukaemia Trust	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the African and Caribbean Leukaemia Trust should be added to the matrix under 'patient/carer' groups.
21.	Anthony Nolan Bone Marrow Trust	PPIP	Added	This organisation's interests are closely related to the appraisal topic and as per our inclusion criteria and equalities commitments. Therefore the Anthony Nolan Bone Marrow Trust should be added to the matrix under 'patient/carer' groups.
22.	CANCERactive	PPIP	Added	This organisation's interests are closely related to the appraisal topic. Therefore CANCERactive should be added to the matrix under 'patient/carer' groups.

8

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of lenalidomide for multiple myeloma in people who have received at least one prior therapy

23.	Helen Rollason Heal Cancer Charity	PPIP	Added	This organisation's interests are closely related to the appraisal topic. Therefore the Helen Rollason Heal Cancer Charity should be added to the matrix under 'patient/carer' groups.
24.	International Myeloma Foundation (UK)	PPIP	Added	This organisation's interests are closely related to the appraisal topic. Therefore the International Myeloma Foundation (UK) should be added to the matrix under 'patient/carer' groups.
25.	Leukaemia Society (U.K.)	PPIP	Added	This organisation's interests are closely related to the appraisal topic. Therefore the Leukaemia Society (UK) should be added to the matrix under 'patient/carer' groups.
26.	UK Myeloma Forum	PPIP	Added	UK Myeloma Forum should be listed in professional (as it is in the bortezomib 18 th wave matrix) with the 'the' removed.
27.	Alan Pharmaceuticals	NICE Secretariat	Added	Alan Pharmaceuticals (thalidomide) added as comparator manufacturer.

9

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of lenalidomide for multiple myeloma in people who have received at least one prior therapy

